The special immunotherapy edition of Perspective magazine is live

Blue Latitude Health | 19th May 2016

As a creative marketing consultancy, we have a unique perspective on the challenges facing the broad range of stakeholders in the healthcare and pharma industry. As such, we've created this magazine to explore those challenges in depth from a variety of viewpoints.

In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. At the time of publication, Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we’ve pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.

 

The immunotherapy special issue covers:

  • Immunology in oncology as a therapy area – what it is, how it works, and where it’s heading from a medical and commercial point of view.
  • Key insights around positioning immuno-oncology products based on our hands-on experience working in this area.
  • What new immunotherapies in oncology mean for cancer patients and the doctors who would prescribe them, and in turn, what that means for pharma.
  • The immuno-therapy patient experience as a customer journey.

 

Click the button below to enter your details and receive your digital copy.

What does programmatic advertising mean for your pharma marketing strategy?

Jiayi Chen | 11th January 2018

Senior Associate Consultant Jiayi Chen explains the benefits and pitfalls of programmatic advertising and reveals how it can impact return on investment in your marketing campaigns.

 

read more

How to measure marketing success: profit vs ROI

Paul Townley-Jones | 4th January 2018

Measuring marketing activity is proving to be a major challenge in pharma. Here, Senior Consultant Paul Townley-Jones explores the meaning of success and gives his tips for measuring efficiency and effectiveness, along with the formula for calculating profit and ROI.

read more

Warning signs: making the most of multichannel marketing

Chris Ross | 5th December 2017

Pharma is making measured progress in its adoption of multichannel marketing. But can it actually measure success? And does it even know what good looks like? Chris Ross interviews Senior Consultant Paul Towney Jones to explore the risks and benefits of increased investment in MCM.

read more